Tuesday, March 31, 2015   

Japan’s Takeda to appeal US$6b diabetes drug verdict
(04-08 15:53)

A US jury ordered Japan’s Takeda Pharmaceuticals to pay US$6 billion in punitive damages over a diabetes drug, but the country’s biggest drug-maker is challenging the move.
The District Court, Western District Louisiana, on Tuesday also ordered a US$3 billion penalty for co-defendant Eli Lilly, as well as US$1.5 million in compensatory damages.
The legal fight was over Actos, a drug used to treat diabetes, as causing a patient's bladder cancer.
Takeda Senior Vice President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.
He said he empathized with the plaintiff but the drug did not cause his cancer.
The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer. –AP

   
Other Business breaking news:
British economy grows faster than expected (1 hr 9 mins ago)
China home prices fall in March: survey (1 hr 11 mins ago)
German unemployment falls to new post-unification low (1 hr 16 mins ago)
No AIIB seat for Taiwan: Beijing (1 hr 31 mins ago)
HK retail sales jump in February (2 hrs 8 mins ago)
Japan backs away from AIIB, Taiwan seeks a seat (2 hrs 32 mins ago)
Kingfisher to close British home-improvement stores (2 hrs 42 mins ago)
New taxi app challenges Uber in Korea (03-31 16:20)
Hang Seng ends higher, Shanghai down (03-31 16:12)
Philips to sell major stake in LED, car lighting arm (03-31 15:48)

More breaking news >>

© 2015 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2015, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.